Regulus Therapeutics Inc

$7.98
(as of Apr 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Regulus Therapeutics Inc

Stock Price
$7.98
Ticker Symbol
RGLS
Exchange
NASDAQ

Industry Information for Regulus Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Regulus Therapeutics Inc

Website
https://www.regulusrx.com
Country
USA
Full Time Employees
34

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fundamentals for Regulus Therapeutics Inc

Market Capitalization
$234,539,872
EBITDA
$-49,693,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.82
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
66,243,400
Percent Owned by Insiders
2.18%
Percent Owned by Institutions
86.69%
52-Week High
52-Week Low

Technical Indicators for Regulus Therapeutics Inc

50-Day Moving Average
200-Day Moving Average
RSI
94.63
ATR
0.6

Analyst Ratings for Regulus Therapeutics Inc

Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About Regulus Therapeutics Inc

Apr 30, 2025, 7:50 AM EST
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus. See more.
Apr 30, 2025, 7:24 AM EST
By Bhanvi Satija and Mariam Sunny See more.
Apr 30, 2025, 7:10 AM EST
Novartis Pharma AG See more.
Apr 30, 2025, 7:10 AM EST
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease Lead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory milestone; transaction is expected to close in the second half of 2025, subject to customary closing conditions See more.